D3-002A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours
ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
First Line
Advanced curatively unresectable solid tumors failing standard therapy.
HCC: must have failed at least 1 line of standard therapy
Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)
Other solid tumours: must have failed at least 1 line of standard therapy
Subscribe to our mailing list to get the updates to your email inbox...